Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.

Abstract: A glaucoma drainage device has a tube shunting the anterior chamber to a drainage location. A power generator has a rotor coupled to a micro-generator. The power generator is configured to generate energy from aqueous flowing through the tube. The force required to drive the rotor can be controlled to control the flow of aqueous through the tube. Alternatively, energy generated by the power generator is stored in a power source that powers an active valve, a pressure sensor, or telemetry.

Abstract: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens.

Abstract: A glaucoma drainage device may comprise a main drainage tube with a first end configured to be located in an anterior chamber of an eye and a second end configured to be located in a drainage location. A bypass drainage tube is fluidly coupled to and in parallel with the main drainage tube. A pump is in communication with the bypass drainage tube. The pump comprises a first driver and a first flexible membrane enclosing a first chamber. A first check valve is located upstream of the pump, and a second check valve is located downstream of the pump. An active valve is located upstream of the first check valve. The active valve comprises a second driver and a second flexible membrane enclosing a second chamber. A third check valve is located between the active valve and the second end of the main drainage tube. A volume of the first chamber is changed to pump fluid from the anterior chamber to the drainage location.

Abstract: A glaucoma drainage device has an active valve configured to be located between an anterior chamber of an eye and a drainage location, a power source coupled to the active valve, and a controller coupled to the power source. A first pressure sensor is located in fluid communication with the anterior chamber, a second pressure sensor is located in the drainage location, and a third pressure sensor located remotely from the first and second pressure sensors. The controller reads the first, second, and third pressure sensors once during a period of time and adjusts the active valve to control intraocular pressure.

Abstract: Ophthalmic drug delivery devices useful for delivery of pharmaceutically active agents to the posterior segment of the eye are disclosed.

Abstract: 1,4-disubstituted-1,2,3-triazole UV absorbing monomers are disclosed. The UV absorbers are particularly suitable for use in intraocular lens materials.

Abstract: Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.

Abstract: The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention.

Abstract: The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation.

Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.

Abstract: An improved surgical cassette for controlling intraocular pressure during ophthalmic surgery.

Abstract: UV absorbing monomers that are particularly useful in ophthalmic devices are disclosed.

Abstract: Disclosed are soft, high refractive index, acrylic device materials. The materials contain a copolymeric additive for glistening resistance.

Abstract: An ophthalmic injection system has a tip segment attachable to and removable from a limited reuse assembly. The tip segment has a dispensing chamber housing, a plunger, a needle, a temperature control device, a thermal sensor, and a first housing at least partially enclosing the dispensing chamber housing, the temperature control device and the plunger. The limited reuse assembly has an actuator with a shaft, a power source for providing power to the actuator, a controller for controlling the actuator, a mechanical linkage interface, and a second housing at least partially enclosing the power source, the controller, and the actuator. The mechanical linkage interface is coupled to the actuator shaft and has a mating surface on one end. The substance is injected after the temperature of the substance is altered.

Abstract: Disclosed are soft, high refractive index, acrylic device materials. The materials comprise di-block or tri-block macromers containing hydrophilic side-chains. The materials have improved glistening resistance.

Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.

Abstract: An injection device assembly includes a dispensing chamber housing and a plunger. The dispensing chamber housing is coupled to a needle. The dispensing chamber housing has an inner surface and an outer surface. The inner surface partially defines a dispensing chamber for holding a quantity of a substance. A dosage of a substance is cast into the dispensing chamber housing or cast onto a plunger that is inserted into the dispensing chamber housing.

Abstract: A viscoelastic composition for injection into a human eye comprised of about 2.0 to 2.5 percent of hydroxypropyl methylcellulose dissolved in a physiological salt solution, the composition, the composition having a viscosity from about 15,000 to about 40,000 centipoise and the hydroxypropyl methylcellulose having a molecular weight from about 220,000 to less than about 420,000 Daltons, the composition being free of debris or gels greater than 0.5 ?m. Also described is a process for preparing the clean, high molecular weight hydroxy propylmethyl cellulose composition.